Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,588 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Descriptive Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Remote Exercise Study for Individuals With Down Syndrome

NCT04647851
View directory record Official record
Conditions
Down Syndrome
Interventions
Remote exercise intervention Down syndrome
Other
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 26, 2026, 2:27 AM EDT
Active, not recruiting Phase 1 Interventional

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

NCT05455294
View directory record Official record
Conditions
Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Interventions
Navitoclax, Venetoclax, Decitabine
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms

NCT01944202
View directory record Official record
Conditions
Inappropriate Use of Echocardiography
Interventions
Educational intervention
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating Mechanisms of Action of Adaptive Goal-Setting for Physical Activity

NCT04505241
View directory record Official record
Conditions
Motivation, Physical Activity Promotion, Behavior Change, Mobile Health
Interventions
Remotely-delivered physical activity promotion
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 26, 2026, 2:27 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Standing Balance as the Fifth Vital Sign in Clinical Setting

NCT04139642
View directory record Official record
Conditions
Accidental Fall, Postural Balance, Clinical Decision-making
Interventions
SimpleSway
Device
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Financial Incentives for Maintenance of Weight Loss

NCT01900392
View directory record Official record
Conditions
Obesity
Interventions
Financial incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Results available

Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM

NCT04203147
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Supportive Therapy (Control), Home DM-BAT
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Genius PillBox Study

NCT06901258
View directory record Official record
Conditions
Older Adults (65 Years and Older)
Interventions
Genius Pillbox
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers

NCT06709755
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Supporting Teen Problem Solving, Diabetes Education
Behavioral
Lead sponsor
Jill Weissberg-Benchell, Ph.D.
Other
Eligibility
14 Years to 18 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

NCT01404949
View directory record Official record
Conditions
Acute Promyelocytic Leukemia
Interventions
Tretinoin and Arsenic Trioxide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
11
States / cities
Los Angeles, California • Evanston, Illinois • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 26, 2026, 2:27 AM EDT
Suspended Not applicable Interventional

A Study of Different Programs to Help ALL Patients With Taking Maintenance Medicine at Home

NCT06639958
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions
Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education
Procedure · Behavioral · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
10 Years to 25 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)

NCT00406419
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00469859
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, idarubicin, lestaurtinib
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cannabis Edibles Packaging Descriptors Experiment

NCT06171399
View directory record Official record
Conditions
Cannabis Use
Interventions
"All Natural" descriptor, "Gluten-free" descriptor, "Vegan" descriptor, "100% Organic" descriptor, "Handcrafted" descriptor, "Made with live resin" descriptor, "Fast-acting" descriptor, "Relax" descriptor, "Energy Boost" descriptor, No descriptor (control)
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
2,521 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Erlotinib, Trastuzumab, and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00042809
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel, trastuzumab, erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

NCT00023998
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
doxorubicin hydrochloride, cisplatin, methotrexate, leucovorin calcium, filgrastim, therapeutic conventional surgery, radiation therapy, etoposide, ifosfamide, trastuzumab, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Phase 3 Interventional

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

NCT01503632
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Behavioral Intervention, Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Questionnaire Administration, Standard Follow-Up Care
Behavioral · Other · Drug + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
100
States / cities
Birmingham, Alabama • Downey, California • Duarte, California + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Recovery, Fatigability, and Proteomic Response to Aerobic Exercise Training in Healthy Individuals

NCT03800342
View directory record Official record
Conditions
Adult, Fatigue
Interventions
Aerobic Exercise Training
Other
Lead sponsor
George Mason University
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional

Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia

NCT00049569
View directory record Official record
Conditions
L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Non-T, Non-B Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Interventions
cytarabine, methotrexate, vincristine sulfate, prednisone, pegaspargase, doxorubicin hydrochloride, imatinib mesylate, cyclophosphamide, etoposide, filgrastim, leucovorin calcium, asparaginase, therapeutic hydrocortisone
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2013 · Synced Oct 26, 2026, 2:27 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

NCT04371666
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Pamrevlumab, Placebo, Corticosteroids
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
12 Years and older · Male only
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients

NCT02724956
View directory record Official record
Conditions
Anesthesia
Interventions
Ambu AuraGain, Teleflex LMA Protector, Ambu aScope
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 26, 2026, 2:27 AM EDT
Recruiting Not applicable Interventional

Positive Processes and Transition to Health (PATH)

NCT06093906
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions
Positive Processes and Transition to Health, Progressive Muscle Relaxation
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Newark, Delaware • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

NCT00047047
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, tanespimycin, cisplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 26, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protective Effect of Exercise on Acute High-fat Overfeeding

NCT07633704
View directory record Official record
Conditions
Insulin Sensitivity/Resistance
Interventions
High Fat Overfeeding, High Fat Overfeeding + Exercise
Behavioral
Lead sponsor
George Washington University
Other
Eligibility
20 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 26, 2026, 2:27 AM EDT